Proteinases, proteinase-activated receptors (PARs) and the pathophysiology of cancer and diseases of the cardiovascular, musculoskeletal, nervous and gastrointestinal systems

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 377, Issue 4-6, 2008, Pages 377-392

  Hansen, Kristina K ^a   Oikonomopoulou, Katerina ^b,c   Li, Yang ^a   Hollenberg, Morley D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cancer; Human tissue kallikreins; Inflammation; Nociception; Proteinase activated receptors; Proteinases

Indexed keywords

CATHEPSIN; G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR RECEPTOR; KALLIKREIN 6; PROSTATE SPECIFIC ANTIGEN; PROTEINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; THROMBIN; THROMBIN RECEPTOR; TISSUE KALLIKREIN; TRYPSIN;

ANALGESIA; ARTHRITIS; ASTROCYTE; ATHEROSCLEROSIS; BLOOD CLOTTING; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR FUNCTION; CELL COMMUNICATION; CELL FUNCTION; CONFERENCE PAPER; CYTOKINE PRODUCTION; ENCEPHALITIS; ENDOTHELIUM CELL; ENTERITIS; ENZYME ACTIVATION; ENZYME ANALYSIS; ENZYME DEGRADATION; GASTROINTESTINAL DISEASE; HEART RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALGESIA; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; INTESTINE FUNCTION; KIDNEY BLOOD VESSEL; METASTASIS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL SYSTEM; MUSCULOSKELETAL SYSTEM INFLAMMATION; MYENTERIC PLEXUS; NERVE CELL; NERVE DEGENERATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NOCICEPTION; NONHUMAN; PERIPHERAL NERVE; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKIN PIGMENTATION; STRUCTURE ACTIVITY RELATION; THROMBOCYTE ACTIVATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION; WHITE MATTER;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; GASTROINTESTINAL DISEASES; HUMANS; MUSCULOSKELETAL DISEASES; NEOPLASMS; NERVOUS SYSTEM DISEASES; PEPTIDE HYDROLASES; RECEPTORS, PROTEINASE-ACTIVATED; SIGNAL TRANSDUCTION;

EID: 45849127939     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0194-2     Document Type: Conference Paper

References (129)

1. Abey HT, Fairlie DP, Moffatt JD, Balzary RW, Cocks TM (2006) Protease-activated receptor-2 peptides activate neurokinin-1 receptors in the mouse isolated trachea. J Pharmacol Exp Ther 317:598-605
2. Ahlquist RP (1948) A study of the adrenotropic receptors. Am J Physiol 153:586-600
3. Ahn HS, Foster C, Boykow G, Stamford A, Manna M, Graziano M (2000) Inhibition of cellular action of thrombin by N3-cyclopropyl-7-[[4-(1- methylethyl)phenyl]methyl]-7H-pyrrolo[3, 2-f]quinazoline-1,3-diamine (SCH 79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 60:1425-1434
4. 2, in rat vascular and gastric smooth muscle. Can J Physiol Pharmacol 73:1203-1207
5. Al-Ani B, Saifeddine M, Wijesuriya SJ, Hollenberg MD (2002) Modified proteinase-activated receptor-1 and -2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin. J Pharmacol Exp Ther 300:702-708
6. Amadesi S, Cottrell GS, Divino L, Chapman K, Grady EF, Bautista F, Karanjia R, Barajas-Lopez C, Vanner S, Vergnolle N, Bunnett NW (2006) Protease-activated receptor 2 sensitizes TRPV1 by protein kinase Cepsilon- and A-dependent mechanisms in rats and mice. J Physiol 575:555-571
7. Andrade-Gordon P, Maryanoff BE, Derian CK, Zhang HC, Addo MF, Darrow AL, Eckardt AJ, Hoekstra WJ, McComsey DF, Oksenberg D, Reynolds EE, Santulli RJ, Scarborough RM, Smith CE, White KB (1999) Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 96:12257-12262
8. Asfaha S, Brussee V, Chapman K, Zochodne DW, Vergnolle N (2002) Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br J Pharmacol 135:1101-1106
9. Asfaha S, Cenac N, Houle S, Altier C, Papez MD, Nguyen C, Steinhoff M, Chapman K, Zamponi GW, Vergnolle N (2007) Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br J Pharmacol 150:176-185
10. Bank U, Heimburg A, Helmuth M, Stefin S, Lendeckel U, Reinhold D, Faust J, Fuchs P, Sens B, Neubert K, Tager M, Ansorge S (2006) Triggering endogenous immunosuppressive mechanisms by combined targeting of Dipeptidyl peptidase IV (DPIV/CD26) and Aminopeptidase N (APN/ CD13)-a novel approach for the treatment of inflammatory bowel disease. Int Immunopharmacol 6:1925-1934
11. Bar-Shavit R, Kahn A, Mudd MS, Wilner GD, Mann KG, Fenton JW 2nd (1984) Localization of a chemotactic domain in human thrombin. Biochemistry 23:397-400
12. Bar-Shavit R, Kahn AJ, Mann KG, Wilner GD (1986) Identification of a thrombin sequence with growth factor activity on macrophages. Proc Natl Acad Sci USA 83:976-980
13. Becker C, Noldus J, Diamandis E, Lilja H (2001) The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. Crit Rev Clin Lab Sci 38:357-399
14. 1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:303-313
15. Borgono CA, Diamandis EP (2004) The emerging roles of human tissue kallikreins in cancer. Nat Rev Cancer 4:876-879
16. Borgono CA, Michael IP, Diamandis EP (2004) Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2:257-280
17. Boven LA, Vergnolle N, Henry SD, Silva C, Imai Y, Holden J, Warren K, Hollenberg MD, Power C (2003) Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J Immunol 170:2638-2646
18. Bushell T (2007) The emergence of proteinase-activated receptor-2 as a novel target for the treatment of inflammation-related CNS disorders. J Physiol 581:7-16
19. Cattaruzza F, Cenac N, Barocelli E, Impicciatore M, Hyun E, Vergnolle N, Sternini C (2006) Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents. Am J Pathol 169:177-188
20. Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N (2002) Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol 161:1903-1915
21. Cenac N, Cellars L, Steinhoff M, Andrade-Gordon P, Hollenberg MD, Wallace JL, Fiorucci S, Vergnolle N (2005) Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm Bowel Dis 11:792-798
22. Cenac N, Andrews CN, Holzhausen M, Chapman K, Cottrell G, Andrade-Gordon P, Steinhoff M, Barbara G, Beck P, Bunnett NW, Sharkey KA, Ferraz JG, Shaffer E, Vergnolle N (2007) Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 117:636-647
23. Cloutier SM, Chagas JR, Mach JP, Gygi CM, Leisinger HJ, Deperthes D (2002) Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. Eur J Biochem 269:2747-2754
24. Corvera CU, Déry O, McConalogue K, Böhm SK, Khitin LM, Caughey GH, Payan DG, Bunnett NW (1997) Mast cell tryptase regulates rat colonic myocytes through proteinase-activated receptor 2. J Clin Invest 100:1383-1393
25. Corvera CU, Déry O, McConalogue K, Gamp P, Thoma M, Al-Ani B, Caughey GH, Hollenberg MD, Bunnett NW (1999) Thrombin and mast cell tryptase regulate guinea-pig myenteric neurons through proteinase-activated receptors-1 and -2. J Physiol 517:741-756
26. Cottrell GS, Amadesi S, Grady EF, Bunnett NW (2004) Trypsin IV, a novel agonist of protease-activated receptors 2 and 4. J Biol Chem 279:13532-13539
27. Coughlin SR (2000) Thrombin signalling and protease-activated receptors. Nature 407:258-264
28. Coughlin SR (2005) Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3:1800-1814
29. Covic L, Misra M, Badar J, Singh C, Kuliopulos A (2002) Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nat Med 8:1161-1165
30. Cuatrecasas P (1971) Perturbation of the insulin receptor of isolated fat cells with proteolytic enzymes. J Biol Chem 246:6522-6531
31. Damiano BP, Cheung WM, Santulli RJ, Fung-Leung WP, Ngo K, Ye RD, Darrow AL, Derian CK, de Garavilla L, Andrade-Gordon P (1999) Cardiovascular responses mediated by protease-activated receptor-2 (PAR-2) and thrombin receptor (PAR-1) are distinguished in mice deficient in PAR-2 or PAR-1. J Pharmacol Exp Ther 288:671-678
32. Darmoul D, Gratio V, Devaud H, Laburthe M (2004) Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem 279:20927-20934
33. de Garavilla L, Vergnolle N, Young SH, Ennes H, Steinhoff M, Ossovskaya VS, D'Andrea MR, Mayer EA, Wallace JL, Hollenberg MD, Andrade-Gordon P, Bunnett NW (2001) Agonists of proteinase-activated receptor 1 induce plasma extravasation by a neurogenic mechanism. Br J Pharmacol 133:975-987
34. Di Sebastiano P, di Mola FF, Artese L, Rossi C, Mascetta G, Pernthaler H, Innocenti P (2001) Beneficial effects of Batimastat (BB-94), a matrix metalloproteinase inhibitor, in rat experimental colitis. Digestion 63:234-239
35. Dulon S, Leduc D, Cottrell GS, D'Alayer J, Hansen KK, Bunnett NW, Hollenberg MD, Pidard D, Chignard M (2005) Pseudomonas aeruginosa elastase disables proteinase-activated receptor 2 in respiratory epithelial cells. Am J Respir Cell Mol Biol 32:411-419
36. Elliott MB, Irwin DM, Diamandis EP (2006) In silico identification and Bayesian phylogenetic analysis of multiple new mammalian kallikrein gene families. Genomics 88:591-599
37. Emami N, Diamandis EP (2007) Human tissue kallikreins: a road under construction. Clin Chim Acta 381:78-84
38. Even-Ram S, Uziely B, Cohen P, Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I, Bar-Shavit R (1998) Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med 4:909-914
39. Felber LM, Borgono CA, Cloutier SM, Kundig C, Kishi T, Ribeiro Chagas J, Jichlinski P, Gygi CM, Leisinger HJ, Diamandis EP, Deperthes D (2005) Enzymatic profiling of human kallikrein 14 using phage-display substrate technology. Biol Chem 386:291-298
40. Ferrell WR, Lockhart JC, Kelso EB, Dunning L, Plevin R, Meek SE, Smith AJ, Hunter GD, McLean JS, McGarry F, Ramage R, Jiang L, Kanke T, Kawagoe J (2003) Essential role for proteinase-activated receptor-2 in arthritis. J Clin Invest 111:35-41
41. Fiorucci S, Mencarelli A, Palazzetti B, Distrutti E, Vergnolle N, Hollenberg MD, Wallace JL, Morelli A, Cirino G (2001) Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc Natl Acad Sci USA 98:13936-13941
42. Glenn KC, Frost GH, Bergmann JS, Carney DH (1988) Synthetic peptides bind to high-affinity thrombin receptors and modulate thrombin mitogenesis. Pept Res 1:65-73
43. Grabarczyk E, Szaflarska-Poplawska A, Goralczyk K, Rosc D (2006) Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in children with ulcerative colitis. Pol Merkuriusz Lek 20:326-328
44. Grant AD, Cottrell GS, Amadesi S, Trevisani M, Nicoletti P, Materazzi S, Altier C, Cenac N, Zamponi GW, Bautista-Cruz F, Lopez CB, Joseph EK, Levine JD, Liedtke W, Vanner S, Vergnolle N, Geppetti P, Bunnett NW (2007) Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol 578:715-733
45. 2 in isolated perfused rat kidney. Am J Physiol Renal Physiol 285:F95-F104
46. Hansen KK, Sherman PM, Cellars L, Andrade-Gordon P, Pan Z, Baruch A, Wallace JL, Hollenberg MD, Vergnolle N (2005) A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci USA 102:8363-8368
47. Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek H, Kennedy AR, Lichtenstein GR, Billings PC (1997) Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 42:1969-1980
48. Henrikson KP, Salazar SL, Fenton JW 2nd, Pentecost BT (1999) Role of thrombin receptor in breast cancer invasiveness. Br J Cancer 79:401-406
49. Hollenberg MD, Compton SJ (2002) International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol Rev 54:203-217
50. 4-derived peptides. Can J Physiol Pharm 79:439-442
51. Hollenberg MD, Laniyonu AA, Saifeddine M, Moore GJ (1993) Role of the amino- and carboxyl-terminal domains of thrombin receptor-derived polypeptides in biological activity in vascular endothelium and gastric smooth muscle: evidence for receptor subtypes. Mol Pharmacol 43:921-930
52. Hollenberg MD, Saifeddine M, Sandhu S, Houle S, Vergnolle N (2004) Proteinase-activated receptor-4: evaluation of tethered ligand-derived peptides as probes for receptor function and as inflammatory agonists in vivo. Br J Pharmacol 143:443-454
53. Houle S, Papez MD, Ferazzini M, Hollenberg MD, Vergnolle N (2005) Neutrophils and the kallikrein-kinin system in proteinase-activated receptor 4-mediated inflammation in rodents. Br J Pharmacol 146:670-678
54. Isozaki Y, Yoshida N, Kuroda M, Handa O, Takagi T, Kokura S, Ichikawa H, Naito Y, Okanoue T, Yoshikawa T (2006) Anti-tryptase treatment using nafamostat mesilate has a therapeutic effect on experimental colitis. Scand J Gastroenterol 41:944-953
55. 1-targeted ligands. J Pharmacol Exp Ther 288:358-370
56. Kawabata A, Kubo S, Nakaya Y, Ishiki T, Kuroda R, Sekiguchi F, Kawao N, Nishikawa H (2004) Distinct roles for protease-activated receptors 1 and 2 in vasomotor modulation in rat superior mesenteric artery. Cardiovasc Res 61:683-692
57. Kelso EB, Lockhart JC, Hembrough T, Dunning L, Plevin R, Hollenberg MD, Sommerhoff CP, McLean JS, Ferrell WR (2006) Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J Pharmacol Exp Ther 316:1017-1024
58. Kimura M, Andersen TT, Fenton JW 2nd, Bahou WF, Aviv A (1996) Plasmin-platelet interaction involves cleavage of functional thrombin receptor. Am J Physiol 271:C54-C60
59. Kinlough-Rathbone RL, Rand ML, Packham MA (1993) Rabbit and rat platelets do not respond to thrombin receptor peptides that activate human platelets. Blood 82:103-106
60. Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Böhm SK, Bunnett NW (1997) Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci USA 94:8884-8889
61. Kono T, Barham FW (1971) Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. J Biol Chem 246:6204-6209
62. 1 thrombin receptor: kinetics, sites of truncation, and implications for thrombolytic therapy. Biochemistry 38:4572-4585
63. Lafleur MA, Hollenberg MD, Atkinson SJ, Knauper V, Murphy G, Edwards DR (2001) Activation of pro-(matrix metalloproteinase-2) (pro-MMP-2) by thrombin is membrane-type-MMP-dependent in human umbilical vein endothelial cells and generates a distinct 63 kDa active species. Biochem J 357:107-115
64. Laumonnier Y, Syrovets T, Burysek L, Simmet T (2006) Identification of the annexin A2 heterotetramer as a receptor for the plasmin-induced signaling in human peripheral monocytes. Blood 107:3342-3349
65. Li Q, Laumonnier Y, Syrovets T, Simmet T (2007) Plasmin triggers cytokine induction in human monocyte-derived macrophages. Arterioscler Thromb Vasc Biol 27:1383-1389
66. Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R (2001) Proteinase-activated receptors. Pharmacol Rev 53:245-282
67. McGuire JJ, Saifeddine M, Triggle CR, Sun K, Hollenberg MD (2004a) 2-furoyl-LIGRLO-amide: a potent and selective proteinase-activated receptor 2 agonist. J Pharmacol Exp Ther 309:1124-1131
68. McGuire JJ, Hollenberg MD, Bennett BM, Triggle CR (2004b) Hyperpolarization of murine small caliber mesenteric arteries by activation of endothelial proteinase-activated receptor 2. Can J Physiol Pharmacol 82:1103-1112
69. Medina C, Radomski MW (2006) Role of matrix metalloproteinases in intestinal inflammation. J Pharmacol Exp Ther 318:933-938
70. Medina C, Videla S, Radomski A, Radomski M, Antolin M, Guarner F, Vilaseca J, Salas A, Malagelada JR (2001) Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease. Scand J Gastroenterol 36:1314-1319
71. Medina C, Santana A, Paz MC, Diaz-Gonzalez F, Farre E, Salas A, Radomski MW, Quintero E (2006) Matrix metalloproteinase-9 modulates intestinal injury in rats with transmural colitis. J Leukoc Biol 79:954-962
72. Menzel K, Hausmann M, Obermeier F, Schreiter K, Dunger N, Bataille F, Falk W, Scholmerich J, Herfarth H, Rogler G (2006) Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin Exp Immunol 146:169-180
73. Mirza H, Schmidt VA, Derian CK, Jesty J, Bahou WF (1997) Mitogenic responses mediated through the proteinase-activated receptor-2 are induced by expressed forms of mast cell alpha- or beta-tryptases. Blood 90:3914-3922
74. Moffatt JD (2007) Proteinase-activated receptors in the lower urinary tract. Naunyn-Schmiedeberg's Arch Pharmacol 375:1-9
75. Molino M, Barnathan ES, Numerof R, Clark J, Dreyer M, Cumashi A, Hoxie JA, Schechter N, Woolkalis M, Brass LF (1997) Interactions of mast cell tryptase with thrombin receptors and PAR-2. J Biol Chem 272:4043-4049
76. Morohoshi Y, Matsuoka K, Chinen H, Kamada N, Sato T, Hisamatsu T, Okamoto S, Inoue N, Takaishi H, Ogata H, Iwao Y, Hibi T (2006) Inhibition of neutrophil elastase prevents the development of murine dextran sulfate sodium-induced colitis. J Gastroenterol 41:318-324
77. Muramatsu I, Laniyonu A, Moore GJ, Hollenberg MD (1992) Vascular actions of thrombin receptor peptide. Can J Physiol Pharmacol 70:996-1003
78. Naito Y, Takagi T, Kuroda M, Katada K, Ichikawa H, Kokura S, Yoshida N, Okanoue T, Yoshikawa T (2004) An orally active matrix metalloproteinase inhibitor, ONO-4817, reduces dextran sulfate sodium-induced colitis in mice. Inflamm Res 53:462-468
79. Napoli C, Cicala C, Wallace JL, de Nigris F, Santagada V, Caliendo G, Franconi F, Ignarro LJ, Cirino G (2000) Protease-activated receptor-2 modulates myocardial ischemia-reperfusion injury in the rat heart. Proc Natl Acad Sci USA 97:3678-3683
80. Napoli C, de Nigris F, Wallace JL, Hollenberg MD, Tajana G, De Rosa G, Sica V, Cirino G (2004) Evidence that protease activated receptor 2 expression is enhanced in human coronary atherosclerotic lesions. J Clin Pathol 57:513-516
81. Nguyen C, Coelho AM, Grady E, Compton SJ, Wallace JL, Hollenberg MD, Cenac N, Garcia-Villar R, Bueno L, Steinhoff M, Bunnett NW, Vergnolle N (2003) Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharm 81:920-927
82. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, D'Andrea MR, Andrade-Gordon P, Karpatkin S (1998) Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 92:3694-3700
83. Noorbakhsh F, Vergnolle N, McArthur JC, Silva C, Vodjgani M, Andrade-Gordon P, Hollenberg MD, Power C (2005) Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J Immunol 174:7320-7329
84. Noorbakhsh F, Tsutsui S, Vergnolle N, Boven LA, Shariat N, Vodjgani M, Warren KG, Andrade-Gordon P, Hollenberg MD, Power C (2006) Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J Exp Med 203:425-435
85. Nystedt S, Emilsson K, Wahlestedt C, Sundelin J (1994) Molecular cloning of a potential proteinase activated receptor. Proc Natl Acad Sci USA 91:9208-9212
86. Oikonomopoulou K, Hansen KK, Saifeddine M, Vergnolle N, Tea I, Blaber M, Blaber SI, Scarisbrick I, Diamandis EP, Hollenberg MD (2006a) Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol Chem 387:817-824
87. Oikonomopoulou K, Hansen KK, Saifeddine M, Tea I, Blaber M, Blaber SI, Scarisbrick I, Andrade-Gordon P, Cottrell GS, Bunnett NW, Diamandis EP, Hollenberg MD (2006b) Proteinase-activated receptors, targets for kallikrein signaling. J Biol Chem 281:32095-32112
88. Ossovskaya VS, Bunnett NW (2004) Protease-activated receptors: contribution to physiology and disease. Physiol Rev 84:579-621
89. Pampalakis G, Sotiropoulou G (2007) Tissue kallikrein proteolytic cascade pathways in normal physiology and cancer. Biochim Biophys Acta 1776:22-31
90. Pan Z, Jeffery DA, Chehade K, Beltman J, Clark JM, Grothaus P, Bogyo M, Baruch A (2006) Development of activity-based probes for trypsin-family serine proteases. Bioorg Med Chem Lett 16:2882-2885
91. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C, Ullrich A (1999) EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402:884-888
92. Quinton TM, Kim S, Derian CK, Jin J, Kunapuli SP (2004) Plasmin-mediated activation of platelets occurs by cleavage of protease-activated receptor 4. J Biol Chem 279:18434-18439
93. Raithel M, Winterkamp S, Pacurar A, Ulrich P, Hochberger J, Hahn EG (2001) Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease. Scand J Gastroenterol 36:174-179
94. Ramachandran R, Hollenberg MD (2007) Proteinases and signaling: pathophysiological and therapeutic implications via PARs and more. Brit J Pharmacol, in press
95. Rasmussen UB, Vouret-Craviari V, Jallat S, Schlesinger Y, Pages G, Pavirani A, Lecocq JP, Pouysségur J, Van Obberghen-Schilling E (1991) cDNA cloning and expression of a hamster alpha-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett 288:123-128
96. 2): a tumor suppressor in skin carcinogenesis. J Invest Dermatol 127:2245-2252
97. Rieser P (1967) The insulin-like action of pepsin and pepsinogen. Acta Endocrinol (Copenhagen) 54:375-379
98. Rieser P, Rieser CH (1964) Anabolic responses of diaphragm muscle to insulin and to other pancreatic proteins. Proc Soc Exp Biol Med 116:669-671
99. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W (2002) Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296:1880-1882
100. Ruf W, Dorfleutner A, Riewald M (2003) Specificity of coagulation factor signaling. J Thromb Haemost 1:1495-1503
101. Sadaghiani AM, Verhelst SH, Bogyo M (2007) Tagging and detection strategies for activity-based proteomics. Curr Opin Chem Biol 11:20-28
102. Saifeddine M, Al-Ani B, Cheng CH, Wang L, Hollenberg MD (1996) Rat proteinase-activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol 118:521-530
103. Saifeddine M, Seymour ML, Xiao YP, Compton SJ, Houle S, Ramachandran R, Macnaughton WK, Simonet S, Vayssettes-Courchay C, Verbeuren TJ, Hollenberg MD (2007) Proteinase-activated receptor-2 activating peptides: Distinct canine coronary artery receptor systems. Am J Physiol Heart Circ Physiol (in press). doi: 10.1152/ajpheart.00519.2007
104. Santana A, Medina C, Paz-Cabrera MC, Diaz-Gonzalez F, Farre E, Salas A, Radomski MW, Quintero E (2006) Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice. World J Gastroenterol 12:6464-6472
105. Shaw JLV, Diamandis EP (2007) Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53:1423-1432
106. 2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2:395-402
107. Shoelson SE, White MF, Kahn CR (1988) Tryptic activation of the insulin receptor. Proteolytic truncation of the alpha-subunit releases the beta-subunit from inhibitory control. J Biol Chem 263:4852-4860
108. Sobey CG, Moffatt JD, Cocks TM (1999) Evidence for selective effects of chronic hypertension on cerebral artery vasodilatation to protease-activated receptor-2 activation. Stroke 30:1933-1940
109. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, Trevisani M, Hollenberg MD, Wallace JL, Caughey GH, Mitchell SE, Williams LM, Geppetti P, Mayer EA, Bunnett NW (2000) Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 6:151-158
110. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, Luger TA, Hollenberg MD (2005) Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev 26:1-43
111. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME, Bird J (1999) The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 13:1535-1542
112. Vergnolle N (2004) Modulation of visceral pain and inflammation by protease-activated receptors. Br J Pharmacol 141:1264-1274
113. Vergnolle N (2005) Clinical relevance of proteinase activated receptors (PARs) in the gut. Gut 54:867-874
114. 2 that regulates intestinal transport. Proc Natl Acad Sci USA 95:7766-7771
115. 1). Br J Pharmacol 126:1262-1268
116. 2)-activating peptides in the rat paw. Br J Pharmacol 127:1083-1090
117. Vergnolle N, Bunnett NW, Sharkey KA, Brussee V, Compton SJ, Grady EF, Cirino G, Gerard N, Basbaum AI, Andrade-Gordon P, Hollenberg MD, Wallace JL (2001a) Proteinase-activated receptor-2 and hyperalgesia: a novel pain pathway. Nat Med 7:821-826
118. Vergnolle N, Wallace JL, Bunnett NW, Hollenberg MD (2001b) Protease-activated receptors in inflammation, neuronal signaling and pain. Trends Pharmacol Sci 22:146-152
119. Vergnolle N, Derian CK, D'Andrea MR, Steinhoff M, Andrade-Gordon P (2002) Characterization of thrombin-induced leukocyte rolling and adherence: a potential proinflammatory role for proteinase-activated receptor-4. J Immunol 169:1467-1473
120. Vergnolle N, Cellars L, Mencarelli A, Rizzo G, Swaminathan S, Beck P, Steinhoff M, Andrade-Gordon P, Bunnett NW, Hollenberg MD, Wallace JL, Cirino G, Fiorucci S (2004) A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 114:1444-1456
121. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63-73
122. Vu TK, Hung DT, Wheaton VI, Coughlin SR (1991) Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64:1057-1068
123. Wang X, Hollenberg MD, Loutzenhiser R (2005) Redundant signaling mechanisms contribute to the vasodilatory response of the afferent arteriole to proteinase-activated receptor-2. Am J Physiol Renal Physiol 288:F65-F75
124. Wanstall JC, Gambino A (2004) Proteinase-activated receptor (PAR)-mediated vasorelaxation in pulmonary arteries from normotensive and hypoxic pulmonary hypertensive rats. Pulm Pharmacol Ther 17:97-103
125. Yang L, Bae JS, Manithody C, Rezaie AR (2007) Identification of a specific exosite on activated protein C for interaction with protease activated receptor 1. J Biol Chem 282:25493-25500
126. Yasothornsrikul S, Hook VYH (2000) Detection of proteolytic activity by fluorescent zymogram in-gel assays. Biotechniques 28:1166-1173
127. Yoon H, Laxmikanthan G, Lee J, Blaber SI, Rodriguez A, Kogot JM, Scarisbrick IA, Blaber M (2007) Activation profiles and regulatory cascades of the human kallikrein-related peptidases. J Biol Chem (in press). doi: 10.1074/jbc.M705190200
128. Yousef GM, Diamandis EP (2002) Human tissue kallikreins: a new enzymatic cascade pathway? Biol Chem 383:1045-1057
129. Zhao Z, Russell PJ (2003) Trypsin activity assay in substrate-specific one- and two-dimensional gels: a powerful method to separate and characterize novel proteases in active form in biological samples. Electrophoresis 24:3284-3288